Humacyte, Inc. (HUMA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$27.00M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$28.93M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$24.39M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$29.73M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$27.00M | (m) | $406.00K | (m) | $104.00K* | -$22.06M* | $1.23M | $18.14M | (m) | $0.00 |
| 2026-03-31 | Reported | (m) | -$28.93M | (m) | $495.00K | (m) | $175.00K | -$25.10M | $2.04M | $19.46M | (m) | $0.00 |
| 2025-09-30 | Reported | (m) | -$24.39M | (m) | $753.00K | (m) | $49.00K* | -$23.90M* | $260.00K | $17.27M | $7.61M | $0.00 |
| 2025-06-30 | Reported | (m) | -$29.73M | (m) | $301.00K | (m) | $568.00K* | -$26.41M* | $213.00K | $22.01M | $7.81M | $0.00 |
| 2025-03-31 | Reported | (m) | -$23.18M | (m) | $517.00K | (m) | $228.00K | -$28.60M | $147.00K | $15.42M | $8.14M | $0.00 |
| 2024-09-30 | Reported | (m) | -$30.23M | (m) | $0.00 | (m) | $934.00K* | -$22.91M* | $0.00 | $22.93M | $7.31M | $0.00 |
| 2024-06-30 | Reported | (m) | -$29.50M | (m) | $0.00 | (m) | $184.00K* | -$21.29M* | $0.00 | $23.75M | $5.75M | $0.00 |
| 2024-03-31 | Reported | (m) | -$26.58M | (m) | $0.00 | (m) | $391.00K | -$27.35M | $0.00 | $21.26M | $5.31M | $0.00 |
| 2023-09-30 | Reported | (m) | -$24.62M | (m) | (m) | (m) | $493.00K* | -$13.01M* | (m) | $18.55M | (m) | $0.00 |
| 2023-06-30 | Reported | (m) | -$26.73M | (m) | (m) | (m) | $485.00K* | -$22.60M* | (m) | $20.54M | (m) | $0.00 |
| 2023-03-31 | Reported | (m) | -$22.51M | (m) | (m) | (m) | $1.15M | -$18.64M | (m) | $17.28M | (m) | $0.00 |
| 2022-09-30 | Reported | (m) | -$23.49M | (m) | (m) | (m) | $211.00K* | -$16.80M* | (m) | $17.34M | (m) | $0.00 |
| 2022-06-30 | Reported | (m) | -$18.53M | (m) | (m) | (m) | $134.00K* | -$16.57M* | (m) | $14.65M | (m) | $0.00 |
| 2022-03-31 | Reported | (m) | -$21.76M | (m) | (m) | (m) | $22.00K | -$18.80M | (m) | $16.31M | (m) | $0.00 |
| 2021-09-30 | Reported | (m) | -$20.54M | (m) | (m) | (m) | $83.00K* | -$30.52M* | (m) | $15.39M | (m) | $0.00 |
| 2021-06-30 | Reported | (m) | -$19.27M | (m) | (m) | (m) | $63.00K* | -$14.68M* | (m) | $14.57M | (m) | $0.00* |
| 2021-03-31 | Reported | (m) | -$19.77M | (m) | (m) | (m) | $29.00K | -$14.54M | (m) | $15.14M | (m) | $0.00 |
| 2020-09-30 | Reported | (m) | -$17.21M | (m) | (m) | (m) | (m) | -$18.05K | (m) | $14.69M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$108.14M | (m) | $2.04M | (m) | $884.00K | -$105.04M | $9.70M | $69.30M | (m) | $0.00 |
| 2024-12-31 | Reported | (m) | -$114.40M | (m) | $0.00 | (m) | $1.57M | -$98.12M | $0.00 | $88.60M | (m) | $0.00 |
| 2023-12-31 | Reported | (m) | -$100.05M | (m) | (m) | (m) | $2.28M | -$73.31M | (m) | $76.55M | (m) | $0.00 |
| 2022-12-31 | Reported | (m) | -$84.58M | (m) | (m) | (m) | $1.05M | -$71.13M | (m) | $63.26M | (m) | $0.00 |
| 2021-12-31 | Reported | (m) | -$81.21M | (m) | (m) | (m) | $220.00K | -$81.19M | (m) | $61.34M | (m) | $0.00 |
| 2020-12-31 | Reported | (m) | -$64.60M | (m) | (m) | (m) | $318.00K | -$55.57M | (m) | $54.08M | (m) | $0.00 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |